{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:22:03Z","timestamp":1792686123263,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      As key regulatory cells, the impact of follicular regulatory T (Tfr) cells, whose function is regulated by V-domain Ig suppressor of T cell activation (VISTA), on downstream immune cells remains unclear. These cellular-level regulatory mechanisms are closely associated with the development of immune escape in ovarian cancer, a disease characterized by severe effector immune cell dysfunction in the tumor microenvironment. This study aims to elucidate the regulatory effects of VISTA\n                      <jats:sup>+<\/jats:sup>\n                      Tfr cells on the functions of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, CD4\n                      <jats:sup>+<\/jats:sup>\n                      CD25\n                      <jats:sup>\u2212<\/jats:sup>\n                      T cells, and B cells, and to reveal their significance in the immune escape of ovarian cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      VISTA-overexpressing and silenced Tfr cell models were constructed\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Through co-culture experiments, CFSE proliferation assays, ELISA, and flow cytometry were employed to investigate the effects of VISTA\n                      <jats:sup>+<\/jats:sup>\n                      Tfr cells on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell proliferation, effector cytokine secretion, and activation status; their regulation of CD4\n                      <jats:sup>+<\/jats:sup>\n                      CD25\n                      <jats:sup>\u2212<\/jats:sup>\n                      T cell proliferation, cytokine secretion, and Th cell differentiation; and their impact on B cell proliferation and antibody secretion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      VISTA\n                      <jats:sup>+<\/jats:sup>\n                      Tfr cells significantly inhibited CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell proliferation, secretion of effector cytokines (IL-2, IFN-\u03b3), and expression of the activation marker CD69, while upregulating their exhaustion molecules (PD-1, CTLA-4). They skewed the differentiation of CD4\n                      <jats:sup>+<\/jats:sup>\n                      CD25\n                      <jats:sup>\u2212<\/jats:sup>\n                      T cells toward a Th2 phenotype and suppressed Th1 and Th17 cell differentiation. Furthermore, they specifically inhibited IgE secretion by B cells, with no significant effect on other antibodies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      VISTA\n                      <jats:sup>+<\/jats:sup>\n                      Tfr cells multi-dimensionally suppress the function of effector immune cells, providing experimental evidence for the potential role of VISTA-targeted strategies in improving anti-tumor immune responses in ovarian cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1704048","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:30:06Z","timestamp":1764311406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["VISTA+ follicular regulatory T cells modulate the function of effector immune cells: implications for ovarian cancer immune escape"],"prefix":"10.3389","volume":"16","author":[{"given":"Yan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huatuo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08257\u20134","article-title":"Cancer cells impair monocyte-mediated T cell stimulation to evade immunity","volume":"637","author":"Elewaut","year":"2025","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev-pathmechdis-012418\u2013013058","article-title":"Monocytes in the tumor microenvironment","volume":"16","author":"Ugel","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2024.12.006","article-title":"Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments","volume":"46","author":"Gupta","year":"2025","journal-title":"Trends Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: A mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104045","article-title":"VISTA: A novel checkpoint for cancer immunotherapy","volume":"29","author":"Gao","year":"2024","journal-title":"Drug Discov Today"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01336\u20136","article-title":"VISTA-mediated immune evasion in cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Exp Mol Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adm8660","article-title":"Targeting conserved TIM3(+)VISTA(+) tumor-associated macrophages overcomes resistance to cancer immunotherapy","volume":"10","author":"Vanmeerbeek","year":"2024","journal-title":"Sci Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1086102","article-title":"VISTA expression and patient selection for immune-based anticancer therapy","volume":"14","author":"Martin","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112655","article-title":"VISTA: A promising target for overcoming immune evasion in gynecologic cancers","volume":"138","author":"Liu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1178792","article-title":"T follicular helper cells and T follicular regulatory cells in autoimmune diseases","volume":"14","author":"Qi","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020\u2013053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1391404","article-title":"Follicular lymphoma regulatory T-cell origin and function","volume":"15","author":"Rodriguez","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31039","article-title":"New insights into follicular regulatory T cells in the intestinal and tumor microenvironments","volume":"238","author":"Cao","year":"2023","journal-title":"J Cell Physiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02093\u20137","article-title":"Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution","volume":"38","author":"Suma","year":"2024","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.02.003","article-title":"The interplay of effector and regulatory T cells in cancer","volume":"33","author":"Roychoudhuri","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00958\u20136","article-title":"Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy","volume":"22","author":"Eschweiler","year":"2021","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715234","article-title":"CD8(+) T cell exhaustion in cancer","volume":"12","author":"Dolina","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216043","article-title":"CD8(+) T cell exhaustion and cancer immunotherapy","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.03.009","article-title":"CD4+CD25+ regulatory T cells in tumor immunity","volume":"34","author":"Chen","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06765.x","article-title":"Increased CD4(+) CD69(+) CD25(-) T cells in patients with hepatocellular carcinoma are associated with tumor progression","volume":"26","author":"Zhu","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.10.007","article-title":"Cytokine profile of CD4(+)CD25(-)FoxP3(+) T cells in tumor-draining lymph nodes from patients with breast cancer","volume":"116","author":"Niakan","year":"2019","journal-title":"Mol Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101220\u2013015603","article-title":"B cell function in the tumor microenvironment","volume":"40","author":"Downs-Canner","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-016-0160-z","article-title":"T cell exhaustion: from pathophysiological basics to tumor immunotherapy","volume":"15","author":"Catakovic","year":"2017","journal-title":"Cell communication signaling: CCS"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.017","article-title":"B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity","volume":"41","author":"Laumont","year":"2023","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03626\u20139","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12935-023-03116\u20130","article-title":"VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy","volume":"23","author":"Shekari","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Sci (New York NY)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409\u2013101212","article-title":"Differentiation of effector CD4 T cell populations (*)","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"New Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108133","article-title":"Ginsenoside Rg1 relieves experimental colitis by regulating balanced differentiation of Tfh\/Treg cells","volume":"100","author":"Jin","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.004","article-title":"The biological functions of T helper 17 cell effector cytokines in inflammation","volume":"28","author":"Ouyang","year":"2008","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.06.013","article-title":"Distinct follicular T cell subsets regulate lymphoma progression and outcomes","volume":"43","author":"Abe","year":"2025","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","article-title":"Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.991840","article-title":"B cell-T cell interplay in immune regulation: A focus on follicular regulatory T and regulatory B cell functions","volume":"10","author":"Tan","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01910","article-title":"Control of germinal center responses by T-follicular regulatory cells","volume":"9","author":"Wing","year":"2018","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0313\u20135","article-title":"VISTA expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Br J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/intimm\/dxx070","article-title":"The immune checkpoint molecule VISTA regulates allergen-specific Th2-mediated immune responses","volume":"30","author":"Ohno","year":"2018","journal-title":"Int Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-14\u20130161","article-title":"The immunological synapse","volume":"2","author":"Dustin","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","article-title":"VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1039\/d1md00185j","article-title":"VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses","volume":"12","author":"Wu","year":"2021","journal-title":"RSC medicinal Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101308","article-title":"VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity","volume":"42","author":"ElTanbouly","year":"2019","journal-title":"Semin Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1352053","article-title":"VISTA\/CTLA4\/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma","volume":"14","author":"Jlassi","year":"2024","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"New Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1704048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T06:30:07Z","timestamp":1764311407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1704048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2025.1704048"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1704048","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1704048"}}